1. Articles in category: Clinical Research

    1-24 of 273 1 2 3 4 ... 10 11 12 »
    1. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma

      Prognosis for relapsed/refractory high-risk neuroblastoma (HR-NBL) remains poor. Bortezomib, a proteasome inhibitor, has shown preclinical activity against NBL as a single agent and in combination with cytotoxic chemotherapy including irinotecan.

      Eighteen HR-NBL patients with primary refractory (n = 8) or relapsed (n = 10) disease were enrolled in a Phase I study using modified Time To Event Continual Reassessment Method.

      Read Full Article
    2. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      Clin Cancer Res. 2017 Apr 21;:

      Authors: Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN

      Read Full Article
    3. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

      Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

      Exp Biol Med (Maywood). 2017 Jan 01;:1535370217706952

      Authors: Cooper JP, Reynolds CP, Cho H, Kang MH

      Abstract Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells.

      Read Full Article
    4. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

      Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.

      J Control Release. 2017 Apr 12;:

      Authors: Monterrubio C, Paco S, Olaciregui NG, Pascual-Pasto G, Vila-Ubach M, Cuadrado-Vilanova M, Mar Ferrandiz M, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NV, Mora J, Sosnik A, Carcaboso AM

      Read Full Article
    5. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.

      Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.

      Int J Oncol. 2017 Apr 07;:

      Authors: Horwacik I, Rokita H

      Abstract Children diagnosed with high risk neuroblastoma have poor prognosis which stimulates efforts to broaden therapies of the neoplasm. GD2-ganglioside (GD2) marks neuroblastoma cells and is a target for monoclonal antibodies.

      Read Full Article
      Mentions: Antibody Treatment
    6. Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567

      Authors: McGinty L, Kolesar J

      Abstract PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.

      Read Full Article
      Mentions: Treatment
    7. Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy

      Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy

      ​WASHINGTON — Among patients with high-risk neuroblastoma, those who had a certain combination of genotypes gained substantial benefit from adding immunotherapy to isotretinoin treatment, while it is uncertain whether those who lacked the combination gained benefit from immunotherapy, according to results from a randomized phase III clinical trial presented here at the AACR Annual Meeting 2017, April 1-5.

      Read Full Article
    8. Neuroblastoma treatment in the post-genomic era.

      Neuroblastoma treatment in the post-genomic era.

      J Biomed Sci. 2017 Feb 08;24(1):14

      Authors: Esposito MR, Aveic S, Seydel A, Tonini GP

      Abstract Neuroblastoma is an embryonic malignancy of early childhood originating from neural crest cells and showing heterogeneous biological, morphological, genetic and clinical characteristics.

      Read Full Article
      Mentions: Treatment ALK MYCN
    9. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study

      The rationale for studying the combination of bevacizumab, irinotecan, and temozolomide (BIT) in neuroblastoma (NB) is based on the following: (i) vascular endothelial growth factor (VEGF) expression is associated with an aggressive phenotype, (ii) anti-VEGF antibody bevacizumab enhances irinotecan-mediated suppression of NB xenografts, (iii) bevacizumab safety has been established in pediatric phase I studies, and (iv) irinotecan + temozolomide (IT) is a standard salvage chemotherapy.

      Read Full Article
    10. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.

      The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.

      J Pediatr Oncol Nurs. 2017 Jan 01;:1043454216680595

      Authors: Secola R, Marachelian A, Cohn SL, Toy B, Neville K, Granger M, Brentlinger A, Martin G

      Read Full Article
    11. Incorporation of high-dose (131) I-metaiodobenzylguanidine treatment into killer immunoglobulin-like receptor/HLA-ligand mismatched haploidentical stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplanta

      Incorporation of high-dose (131) I-metaiodobenzylguanidine treatment into killer immunoglobulin-like receptor/HLA-ligand mismatched haploidentical stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation.

      Pediatr Blood Cancer. 2016 Dec 24;:

      Authors: Lee JW, Kang ES, Sung KW, Yi E, Lee SH, Yoo KH, Koo HH

      Read Full Article
      Mentions: Treatment MIBG GvHD
    12. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.

      Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.

      Pediatr Blood Cancer. 2016 Aug 24;

      Authors: Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, Garaventa A, Gambart M, Bautista F, Valteau-Couanet D, Geoerger B, Vassal G, Paoletti X, Pearson AD

      Read Full Article
      Mentions: SIOPEN Refractory
    13. Study Finds DFMO Significantly Increases Survival for Children with...

      "101 children took part in the study, receiving oral DFMO over a two-year period, with minimal side effects reported. At the completion of the study, the event-free survival (EFS)* rate for the children who participated was 88%. That’s nearly a 20% increase from the typical EFS rate for children two years into remission. In addition, the study demonstrated a 99% overall survival rate at 2 years."

      Read Full Article
      Mentions: Relapse DFMO NMTRC
    14. Response-based Treatment of High-risk Neuroblastoma

      Condition :   Newly Diagnosed High Risk Neuroblastoma Interventions :   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Carboplatin;   Procedure: Tandem HDCT/auto-SCT;   Radiation: Radiotherapy;   Drug: Interleukin-2;   Drug: Isotretinoin;   Radiation: MIBG Sponsor :   Samsung Medical Center Recruiting - verified May 2016

      Read Full Article
    15. A Phase I/II, Multicenter, OPEN-LABEL, DOSE-ESCALATION Study Of The Safety And Pharmacokinetics Ofcobimetinib In Pediatric And Young Adult Patients With Previously Treated Solid Tumors

      EudraCT Number: 2014-004685-25Sponsor Protocol Number: GO29665Sponsor Name: F. Hoffmann-La Roche LtdStart Date: 2016-04-28Medical condition: Solid TumorsDisease: Version: 19.0SOC Term: 100000004864Classification Code: 10065252Term: Solid tumorLevel: LLTPopulation Age: Children, Adolescents, Under 18, AdultsGender: Male, FemaleTrial Protocol: DE (Ongoing)

      Read Full Article
    16. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.

      A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.

      Pediatr Blood Cancer. 2016 Apr 19;

      Authors: Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP

      Read Full Article
    17. A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

      "This study adds an experimental treatment with another type of cells, called dendritic cells. It is hoped that these cells may stimulate the immune system to react against neuroblastoma in much the same way that vaccines cause the immune system to react to certain viruses and bacteria. The physicians conducting this study have observed from previous research that neuroblastoma cells can be recognized by the immune system, and that they can be destroyed by immune cells.The main goal of this study is to see if giving participants this additional anti-Neuroblastoma vaccine reduces the risk of relapse following the Hematopoietic ...

      Read Full Article
    1-24 of 273 1 2 3 4 ... 10 11 12 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (2 articles) Antibody
    2. (2 articles) Immunotherapy
    3. (1 articles) Nanoparticles
  4. General Informations in the News

    1. (4 articles) Treatment
  5. Treatments in the News

    1. (1 articles) Refractory
    2. (1 articles) Chemotherapy